A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s631, 2025. DOI: 10.25251/h9van576. Disponível em: https://skin.dermsquared.com/skin/article/view/3782. Acesso em: 19 apr. 2026.